Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Metabolic beneficial effects of targeting a long non-coding RNA, lnc-megacluster, in obesity

Abdollahi M., Malek V., Tanwar VS., Kato M., Lanting L., Rezaei A.

Laboratory Study on Type 2 Diabetes, Chronic Kidney Disease, published in Mol Ther Nucleic Acids (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Mol Ther Nucleic Acids (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41532014
PMCID
PMC12794071
DOI
10.1016/j.omtn.2025.102792
Citations
1

Abstract (original English)

The long noncoding RNA (lncRNA) lnc-megacluster (lncMGC) is implicated in diabetic kidney disease and pancreatic islet dysfunction. However, its role in obesity and insulin resistance (IR) is unknown. Herein, we investigated the regulatory role of lncMGC in obesity and adipose dysfunction using lncMGC knockout-(KO) mice and further determined the translational potential of lncMGC-based therapeutics for obesity using GapmeR antisense oligonucleotides in wild-type and partially humanized-lncMGC mice. We found lncMGC is upregulated in perigonadal white adipose (gWAT) and brown adipose tissues (BAT) from high-fat diet (HFD)-induced obese mice along with increased endoplasmic reticulum stress signaling. Inhibition of lncMGC in mice via genetic ablation or GapmeRs targeting mouse or human lncMGC displayed protective effects against HFD-induced IR, weight gain, and associated adipose dysfunction, with some sex-specific differences. In parallel, key lncMGC targets regulating gWAT and BAT functions were altered. In gWAT, loss of lncMGC either in KO mice or through GapmeR treatment improved angiogenesis and reduced adipocyte hypertrophy and inflammation. In BAT, lncMGC deficiency or inhibition enhanced mitochondrial thermogenesis and mitophagy markers. Collectively, these new findings underscore the pathogenic role of lncMGC in adipose dysfunction and the therapeutic potential of targeti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research